Drug intelligence / Profile preview

DPV-008

Development stage: Preclinical
Lead developer: UbiVac
Modality: Vaccines & Immunotherapeutics
Administration: Intranodal Injection

Overview

DPV-008 is a DRibble vaccine candidate developed by Ubivac for the treatment of thyroid cancer. The DRibble technology platform involves the use of short-lived proteins that accumulate as ubiquitin-conjugated proteins and are released from tumor cells as particles, which can then be used to stimulate an immune response against cancer cells. This approach is designed to harness the body's own immune system to detect and destroy cancer cells, functioning as a form of immunotherapy[1][2].

Other names: DPV-008DPV008DPV 008

Beyond the preview

Go deeper on DPV-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPV-008.

Explore the full profile